Keywords
How to Cite
Abstract
The recent and ongoing coronavirus pandemic has taken over almost the entire world. Despite the severity of the COVID-19 problem, mortality from this disease is in no way comparable to mortality from cardiovascular disease (CVD), which remains the leading cause of death among the population. Of course, the increase in mortality directly and indirectly depends on the clinical forms of this virus
References
1. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA cardiology. 2020; doi:10.1001/jamacardio.2020.1017 2. Batlle D, Wysocki J, Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clin Sci. 2020;134(5):543-5.
3. Gallagher P, Ferrario C, Tallant E. Regulation of ACE 2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol. 2008;295(6):H2373-H2379.
4. Imai Y, Kuba K, Penninger JM. The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. Experimental Physiology. 2008;93(5):543-8.
5. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112-6.
6. Gallagher P, Ferrario C, Tallant E. Regulation of ACE 2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol. 2008;295(6):H2373-H2379. 7. Imai Y, Kuba K, Penninger JM. The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. Experimental Physiology. 2008;93(5):543-8.